I-Mab

News

AbbVie has claimed rights to an immuno-oncology antibody from I-Mab in what is thought to be a record licensing deal involving a Chinese biotech.

News

Lundbeck has completed patient randomisation in a pivotal trial of epilepsy candidate bexicaserin, one of its major growth hopes.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.